Group 1 - The board of directors of Rongchang Biopharmaceuticals held its 28th meeting, with all 9 directors present, confirming compliance with relevant laws and regulations [1][2] - The board approved the unaudited consolidated financial statements for the six months ending June 30, 2025, which were reviewed by the audit committee [1][3] - The board decided not to declare an interim dividend for 2025, considering the company's overall financial condition and capital needs [2][3] Group 2 - The board approved the company's 2025 interim report and its summary, ensuring compliance with regulations and confirming the accuracy and completeness of the information [2][3] - A special report on the use of raised funds for the first half of 2025 was also approved, with details available on the Shanghai Stock Exchange website [3][5] - The board reviewed and confirmed the effectiveness of the company's risk management and internal control systems for the first half of 2025 [4][5] Group 3 - The board confirmed compliance with the Corporate Governance Code and related rules, with no violations reported during the first half of 2025 [4][5] - An evaluation report on the "Quality Improvement and Efficiency Enhancement" action plan for 2025 was approved, summarizing the execution status for the first half of the year [4][5] - The board approved changes to the registered capital and amendments to the company's articles of association following the issuance of 19 million H shares on May 29, 2025 [5][6] Group 4 - The board reviewed the progress of the company's Environmental, Social, and Governance (ESG) goals for 2025, focusing on sustainable development and social responsibility [5][6]

Group 1 - The company held its 21st meeting of the second board of directors, with all 8 directors present, ensuring compliance with relevant laws and regulations [1][2] - The board approved the 2024 General Manager's Work Report, emphasizing the importance of scientific decision-making and operational compliance [2][3] - The board also approved the 2024 Board of Directors' Work Report, focusing on maintaining company interests and enhancing governance [2][3] Group 2 - The board approved the 2024 Independent Directors' Work Report, highlighting the independent directors' commitment to their duties and company governance [2][3] - A special opinion on the independence assessment of independent directors was approved, confirming their compliance with relevant regulations [3][4] - The 2024 Financial Settlement Report was approved, with financial statements audited by Ernst & Young, showing no reservations [4][5] Group 3 - The board approved the 2024 Annual Report and its summary, ensuring compliance with stock exchange regulations [4][5] - The 2024 Internal Control Evaluation Report was approved, indicating no significant deficiencies in the internal control system [5][6] - The board decided not to distribute profits for 2024, reporting a net loss of 146.84 million yuan [6][7] Group 4 - The board confirmed the remuneration of senior management for 2024 and proposed adjustments for 2025 based on various factors [6][7] - The board approved the remuneration of directors for 2024, with proposals for 2025 to be based on similar considerations [7][8] - An ESG report for 2024 was approved, reflecting the company's commitment to social responsibility [8][9] Group 5 - The board approved the annual performance report of the Audit Committee, confirming its effective operation [8][9] - A general authorization for share issuance was proposed, allowing the board to issue up to 20% of the total shares [9][10] - The board approved the 2025 "Quality Improvement and Efficiency Enhancement" action plan, aimed at optimizing operations and governance [10][11] Group 6 - The board approved a report on the use of raised funds, ensuring compliance with relevant regulations [11][12] - The board agreed to renew the appointment of Ernst & Young as the auditing firm for 2025 [12][13] - A proposal for a comprehensive credit facility of up to 5.5 billion yuan was approved [13][14] Group 7 - The company plans to use up to 500 million yuan for cash management through safe and liquid financial products [14][15] - The board approved the use of idle raised funds for cash management, with a limit of 140 million yuan [15][16] - The board reviewed the risk management and internal control systems for 2024, confirming their effectiveness [16][17] Group 8 - The board confirmed compliance with the Corporate Governance Code and related rules [17][18] - The board approved the evaluation report on the performance of the auditing firm for 2024, affirming its adherence to auditing standards [18]